Last reviewed · How we verify

NCT06111677

SOFA and APACHE II Scoring Systems for Predicting Outcome of Neurological Patients Admitted in a Tertiary Hospital Intensive Care Unit

Completed Last updated 1 November 2023
What this trial tests

trial in Neurologic Disorder in 153 participants. Completed in 1 September 2023.

Timeline
15 April 2023
Primary endpoint
1 August 2023
1 September 2023

Quick facts

Lead sponsorTribhuvan University Teaching Hospital, Institute Of Medicine.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment153
Start date15 April 2023
Primary completion1 August 2023
Estimated completion1 September 2023
Sites1 location across Nepal

Conditions studied

Sponsor

Tribhuvan University Teaching Hospital, Institute Of Medicine.

Who can join

Eligibility, any sex, with Neurologic Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study was to compare the discriminative power of commonly used scoring systems, namely the sequential organ failure assessment (SOFA) and acute physiology and chronic health evaluation II (APACHE II) in the intensive care unit of a tertiary care hospital.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. SOFA and APACHE II scoring systems for predicting outcome of neurological patients admitted in a tertiary hospital intensive care unit.
    Shahi S, Paneru H, Ojha R, Karn R, et al · · 2024 · cited 7× · PMID 38576938 · DOI 10.1097/ms9.0000000000001734

Verify or expand the search:

Other recruiting trials for Neurologic Disorder

Currently open trials in the same condition.

Other Tribhuvan University Teaching Hospital, Institute Of Medicine. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06111677.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing